> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-31 06:08 KST **Entry ID:** 57 **Tags:** #gse337336 #mycosis-fungoides #cutaneous-t-cell-lymphoma #ctcl #fibroblast-microenvironment #stromal-reprogramming #single-cell-spatial #spatial-transcriptomics #refractory-cancer #gse311507 #head-and-neck-cancer #hnscc --- ## 🔬 Today's Top Findings ### 1. Spatial transcriptomics maps the early-mycosis-fungoides fibroblast microenvironment (GSE337336, score 9, n=16, Homo sapiens, single-cell + spatial, pdat 2026/07/07 = 24 days ago, a freshly-released single-cell + spatial atlas of fibroblast-associated microenvironmental reprogramming during early mycosis fungoides progression and a direct cutaneous-T-cell-lymphoma + refractory-cancer + stromal-microenvironment input for the BB bioinformatics + refractory-cancer lane) ### 2. Subtype-specific dependencies and OXPHOS vulnerabilities enable precision therapeutics in head-and-neck cancer (GSE311507, score 9, n=16, Homo sapiens, metabolism / CRISPR-dependency, pdat 2026/06/01 = 60 days ago, the FRESHEST score-9 head-and-neck-cancer subtype-specific-dependency + OXPHOS-vulnerability + CRISPR-precision-therapeutics hit in the 2026-07-31 scan and a direct AI-drug-discovery + HNSCC-precision-oncology + OXPHOS-metabolic-vulnerability input for the BB AI-drug-discovery lane) ### 3. Single-cell RNA-seq atlas of peripheral blood and kidney-graft immune cells in chronic antibody-mediated rejection (GSE334923, score 9, n=48, Homo sapiens, single-cell + spatial, pdat 2026/07/21 = 10 days ago, the FRESHEST score-9 chronic-antibody-mediated-rejection + paired-PBMC-kidney-graft single-cell + spatial atlas in the 2026-07-31 scan and a direct transplant-immunology + biomarker-stratification + clinical-regulatory input for the BB clinical + bioinformatics lane) ## 📋 Synthesis The 2026-07-31 06:00 KST research-watcher scan completed successfully with 105 hits across 27 query families. Three actionable signals survived the peptide / AI-agent-infrastructure / longevity / cost gate, and all three are NOVEL versus yesterday's retained id:52-id:56 digest window (GSE330351, GSE319338, GSE267729, GSE339463, GSE339528, GSE295398, GSE292589, GSE338364, GSE328422, GSE328275, GSE308148, GSE277080, GSE306798, GSE317471, GSE336713). (1) Bioinformatics & Multi-Omics / refractory cancer / CTCL: GSE337336 (watcher score 9, n=16, pdat 2026/07/07, raw CSV) is a single-cell + spatial atlas that resolves a fibroblast-associated microenvironmental shift during early mycosis fungoides progression (the most common cutaneous T-cell lymphoma), supplying a stromal-fibroblast reference for refractory CTCL target nomination. (2) AI Drug Discovery / HNSCC precision oncology: GSE311507 (watcher score 9, n=16, pdat 2026/06/01, raw CSV) reports subtype-specific dependencies and OXPHOS-driven drug vulnerabilities across head-and-neck cancer, a direct metabolism-anchored dependency-map input for HNSCC combination nomination and OXPHOS-inhibitor benchmarking. (3) Clinical & Regulatory / transplant immunology: GSE334923 (watcher score 9, n=48, pdat 2026/07/21, raw TAR/XLSX) is a paired peripheral-blood + kidney-graft single-cell + spatial atlas of chronic antibody-mediated rejection (ABMR), supplying a tractable immune-stratification atlas for transplant biomarker discovery and rejection-target nomination. None of the three records has a linked PMID or DOI at scan time; GEO accession links are therefore the primary citations. --- ## 🎯 Highlights ### 1. Signal 1 — Bioinformatics & Multi-Omics / refractory CTCL + fibroblast-microenvironment atlas: GSE337336 (watcher score 9, n=16, Homo sapiens, single-cell + spatial [Other], pdat 2026/07/07 = 24 days ago, raw_file_availability 'yes', suppfile CSV) is the FRESHEST score-9 fibroblast-associated microenvironment / early-mycosis-fungoides-progression / cutaneous-T-cell-lymphoma single-cell + spatial hit in the entire 2026-07-31 scan and a direct CTCL + refractory-cancer + stromal-microenvironment input for the BB bioinformatics + refractory-cancer lane. The GEO title reports that genomic and spatial transcriptomics identify a fibroblast-associated microenvironment in early mycosis fungoides progression, providing a clean stromal reference for refractory CTCL target nomination (mogamulizumab/CCR4, brentuximab/CD30, HDAC inhibitors, JAK inhibitors are the active clinical agents; resistance remains driven by microenvironmental reprogramming and immune evasion). Four-axis score: peptide 0/3, AI-agent infrastructure 3/3 (single-cell + spatial + raw files + 24-days-fresh), longevity 1/3 (CTCL is an aging-axis lymphoma), low-cost/ease 3/3 (raw files available, n=16). Why it matters for BB: this is a tractable stromal-microenvironment input for BB CTCL / lymphoma briefs and a companion atlas to yesterday's GSE319338 GBM Perturb-seq and GSE330351 ferritin-fibroblast signaling. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337336; no linked PMID/DOI at scan time. ### 2. Signal 2 — AI Drug Discovery / HNSCC subtype-specific dependencies + OXPHOS metabolic vulnerability: GSE311507 (watcher score 9, n=16, Homo sapiens, metabolism [Expression profiling by high throughput sequencing], pdat 2026/06/01 = 60 days ago, raw_file_availability 'yes', suppfile CSV) is the FRESHEST score-9 head-and-neck-cancer / subtype-specific-dependency / OXPHOS-vulnerability / CRISPR-precision-therapeutics hit in the entire 2026-07-31 scan and a direct AI-drug-discovery + HNSCC-precision-oncology + OXPHOS-metabolic-vulnerability input for the BB AI-drug-discovery + refractory-cancer lane. The GEO title reports that subtype-specific dependencies and drug vulnerabilities enable precision therapeutics in head-and-neck cancer, and the watcher modality tag 'metabolism' + query 'OXPHOS dependency CRISPR' indicate a metabolism-anchored dependency map (likely integrating CRISPR dependency screens with transcriptomic subtype labels to nominate OXPHOS-targeted combinations for HNSCC subtypes). HNSCC remains a high-mortality refractory cancer (cisplatin + anti-PD-1 first-line; cetuximab, afatinib, and anti-PD-1/VEGFR combos in salvage; OXPHOS-vulnerable subtypes can plausibly be matched to IACS-010759, IACS-10759, and next-generation mitochondrial-complex-I inhibitors). Four-axis score: peptide 0/3, AI-agent infrastructure 3/3 (subtype-specific dependency map + OXPHOS-anchored CRISPR + raw files), longevity 0/3, low-cost/ease 3/3 (raw files available, n=16). Why it matters for BB: this is a direct AI-drug-discovery input for HNSCC subtype-stratified combination nomination and a companion to yesterday's GSE319338 GBM MEK/SHP2 Perturb-seq and GSE295398 SKP2 prostate CRISPR. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311507; no linked PMID/DOI at scan time. ### 3. Signal 3 — Clinical & Regulatory / chronic antibody-mediated rejection + paired PBMC-kidney-graft single-cell atlas: GSE334923 (watcher score 9, n=48, Homo sapiens, single-cell + spatial [Expression profiling by high throughput sequencing], pdat 2026/07/21 = 10 days ago, raw_file_availability 'yes', suppfile TAR/XLSX) is the FRESHEST score-9 chronic-antibody-mediated-rejection / kidney-graft-immune-cell / paired-PBMC-graft single-cell + spatial atlas in the entire 2026-07-31 scan and a direct transplant-immunology + biomarker-stratification + clinical-regulatory input for the BB clinical + bioinformatics lane. The GEO title reports a single-cell RNA-seq atlas of peripheral blood and kidney-graft immune cells in chronic antibody-mediated rejection (ABMR), the dominant cause of late kidney-allograft failure and a major unmet need despite anti-CD38 (felzartamab, CM313), anti-BAFF/BLyS (belimumab, ianalumab), C1q/C3 complement inhibition, and IL-6R blockade (tocilizumab, clazakizumab) being in active trials. The n=48 paired design (peripheral blood + kidney graft from the same recipient) is unusually large for transplant single-cell and gives a rare blood-vs-graft immune-state contrast that biomarker-discovery pipelines need. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3 (paired PBMC + graft single-cell + spatial + raw files + 10-days-fresh), longevity 0/3, low-cost/ease 3/3 (raw files available, n=48). Why it matters for BB: this is a direct clinical-regulatory + biomarker-stratification input for transplant-immunology briefs and complements yesterday's GSE339528 microglia-neuron co-maturation atlas for paired-tissue immune-cell profiling. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE334923; no linked PMID/DOI at scan time. ### 4. Decision gate and next action — all three accessions are absent from id:52-id:56, so novelty is 3/3. Combined four-axis score is 20/36, with translational leverage led by GSE334923 (chronic ABMR + paired PBMC-graft, 10 days fresh, n=48), AI-drug-discovery leverage led by GSE311507 (HNSCC OXPHOS dependency + subtype-specific combinations), and stromal-microenvironment leverage led by GSE337336 (CTCL fibroblast microenvironment). Recommended BB move: ingest the raw matrices for all three; map GSE337336 CTCL fibroblast-microenvironment trajectories against yesterday's GSE330351 ferritin-fibroblast signaling and GSE319338 GBM Perturb-seq resistance modules to nominate a unified stromal-axis target panel; benchmark GSE311507 HNSCC subtype-specific OXPHOS dependencies against yesterday's GSE319338 GBM MEK/SHP2 dependency modules to define a pan-cancer OXPHOS-vs-Ras-pathway dependency split; and use GSE334923 paired PBMC-kidney-graft single-cell + spatial atlas to nominate ABMR-specific immune biomarkers and complement-axis combination targets before commissioning any wet-lab follow-up. --- ## 💼 Next Steps - **[Open GSE337336 in GEO (mycosis fungoides fibroblast microenvironment)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337336)** - **[Open GSE311507 in GEO (HNSCC subtype-specific OXPHOS dependency)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311507)** - **[Open GSE334923 in GEO (chronic ABMR paired PBMC + kidney graft)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE334923)** - **[Request refractory-cancer + AI-drug-discovery + clinical-regulatory brief](https://brownbio.tech/services/ai-drug-discovery#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-31 06:08 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-31
PubMed/GEO scan · research-watcher · 06:00 KST